Question 1

What is IN8bio's focus?

Accepted Answer

IN8bio is a leading clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors.

Question 2

What is the company's platform technology?

Accepted Answer

IN8bio's platform, called Deltex, employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies designed to effectively identify and eradicate tumor cells.

Question 3

What are IN8bio's lead product candidates?

Accepted Answer

IN8bio's lead product candidates are INB-400, currently in a Phase 2 clinical trial for the treatment of newly diagnosed glioblastoma (GBM), and INB-100, in a Phase 1 clinical trial for the treatment of patients with leukemia undergoing hematopoietic bone marrow transplantation.

Question 4

What is IN8bio's mission?

Accepted Answer

IN8bio's mission is to advance next-generation cancer treatments, referred to as "cancer zero" - the elimination of all cancer cells in every patient battling the disease.

Question 5

How does IN8bio's technology work?

Accepted Answer

IN8bio's technology utilizes genetically modified gamma-delta (γδ) T cells, which are naturally occurring immune cells with unique properties, to effectively identify and eradicate tumor cells.

IN8bio

Company Overview

Company Name

Address

Website

Phone

About IN8bio

Frequently Asked Questions about IN8bio

What is IN8bio's focus?

What is the company's platform technology?

What are IN8bio's lead product candidates?

What is IN8bio's mission?

How does IN8bio's technology work?

Social Profiles

Key Decision Makers